| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/17/2005 | WO2005014599A1 Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| 02/17/2005 | WO2005014597A1 N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO |
| 02/17/2005 | WO2005014584A1 3-(indol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones,3-(benzimidazol-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones, and 3-(indolin-1-yl)-4-(indol-3-yl)-pyrrole-2,5-diones; their preparation and use as modulators of apoptosis |
| 02/17/2005 | WO2005014580A1 Pyridyl piperazinyl ureas |
| 02/17/2005 | WO2005014579A1 Imidazol derivatives of piperdine as histamine antagonists |
| 02/17/2005 | WO2005014576A1 Isoquinolinone derivative, process for producing the same and use thereof |
| 02/17/2005 | WO2005014572A1 Pyrimidylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005014561A1 Compounds having thrombopoietin receptor agonism |
| 02/17/2005 | WO2005014558A1 Condensed pyramidine compounds as inhibitors of voltage-gated ion channels |
| 02/17/2005 | WO2005014548A1 Process for producing low-melting crystal of free disopyramide base |
| 02/17/2005 | WO2005014544A1 Stable modifications of tegaserod hydrogen maleate |
| 02/17/2005 | WO2005014543A1 Condensed ring compound and use thereof as hcv polymerase inhibitor |
| 02/17/2005 | WO2005014529A1 2- adamantyl derivatives as p2x7 receptor antagonists. |
| 02/17/2005 | WO2005014528A1 Straight-chain and branched-chain lipid compounds as selective inhibitors of cyclooxygenase-2, anti-inflammatory agents, and anti-cancer agents |
| 02/17/2005 | WO2005014516A1 Conjugated linolenic acids and methods of preparation and purification and uses thereof |
| 02/17/2005 | WO2005014090A1 Methods of determining film thicknesses for an aerosol delivery article |
| 02/17/2005 | WO2005014048A1 Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| 02/17/2005 | WO2005014046A2 Compositions for delivery of therapeutics into the eyes and methods for making and using the same |
| 02/17/2005 | WO2005014044A1 Medicaments for inhalation comprising betamimetics and an anticholinergic |
| 02/17/2005 | WO2005014043A1 Chlorthalidone combinations |
| 02/17/2005 | WO2005014042A1 HEART-SLOWING DRUG CONTAINING SHORT-ACTING β BLOCKER AS THE ACTIVE INGREDIENT |
| 02/17/2005 | WO2005014030A1 Method for treating lung diseases associated with ventilation-perfusion mismatches |
| 02/17/2005 | WO2005014027A1 Use of chemokines, and pharmaceutical preparations containing the same |
| 02/17/2005 | WO2005014020A1 Compositions incorporating high-caffeine green tea extract and related methods for promoting healthy body weight |
| 02/17/2005 | WO2005014014A1 Method for inhibiting bacterial colonisation |
| 02/17/2005 | WO2005014013A1 Viscosity-stable bismuth-containing pharmaceutical compositions |
| 02/17/2005 | WO2005014012A1 New therapeutic use of chondroitin sulphate |
| 02/17/2005 | WO2005014010A1 Pharmaceutical composition comprising gemcitabine and cyclodextrines |
| 02/17/2005 | WO2005014009A1 Glycyrrhizin high-concentration preparation |
| 02/17/2005 | WO2005014008A2 Treatment of disorders associated with natural killer t cells |
| 02/17/2005 | WO2005014007A1 Compounds for the treatment of autoimmune and demyelinating diseases |
| 02/17/2005 | WO2005014006A1 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss |
| 02/17/2005 | WO2005014005A1 Combination of an anticholinergic and a steroid and its use to treat respiratory disorders by inhalation |
| 02/17/2005 | WO2005014003A1 Topical use of tyrosine kinase inhibitors of microbial origin to prevent and treat skin disorders characterised by excessive cell proliferation |
| 02/17/2005 | WO2005014002A1 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders |
| 02/17/2005 | WO2005014001A1 Use of 2h- [1, 3] - oxazino [3, 2-a] indole derivatives for the treatment of neuropathic pain |
| 02/17/2005 | WO2005014000A1 Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity |
| 02/17/2005 | WO2005013999A1 Medicaments for inhalation comprising steroids and a novel anticholinergic |
| 02/17/2005 | WO2005013996A2 2,4-pyrimidinediamine compounds and uses as anti-proliferative agents |
| 02/17/2005 | WO2005013995A1 4-substituted 7-alkoxy-2-aminosulfonyl-1,2-dihydro-phtalazin derivatives as phosphodiesterase 4 inhibitors for the treatment of allergies and inflammations |
| 02/17/2005 | WO2005013994A1 Medicaments for inhalation comprising anticholinergics and a betamimetic |
| 02/17/2005 | WO2005013993A1 Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
| 02/17/2005 | WO2005013992A1 Medicaments for inhalation comprising betamimetics and an anticholinergic agent |
| 02/17/2005 | WO2005013991A1 Dry syrup containing loratadine |
| 02/17/2005 | WO2005013989A1 Use of indazole derivatives for the treatment of neuropathic pain |
| 02/17/2005 | WO2005013987A1 Fexofenadine composition and process for preparing |
| 02/17/2005 | WO2005013986A1 Pyridylpyrrole derivatives active as kinase inhibitors |
| 02/17/2005 | WO2005013985A1 Treatment for alzheimer's disease and related conditions |
| 02/17/2005 | WO2005013984A1 Selective serotonin reuptake inhibitors for the treatment of premature female orgasm |
| 02/17/2005 | WO2005013983A1 Combination of src kinase inhibitors and chemotherapeutic agents for the treatment of proliferative diseases |
| 02/17/2005 | WO2005013980A1 Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions. |
| 02/17/2005 | WO2005013973A1 Semi-solid systems containing azetidine derivatives |
| 02/17/2005 | WO2005013972A1 Emulsifying systems containing azetidine derivatives |
| 02/17/2005 | WO2005013971A1 Pharmaceutical compositions comprising ascorbic acid for the treatment of fungal superfinfections and fungal recurrences |
| 02/17/2005 | WO2005013970A1 Agent for improving hepatobiliary disorder |
| 02/17/2005 | WO2005013969A1 Antipsychotic agent with socializing properties |
| 02/17/2005 | WO2005013968A1 Semi-solid formulations for the oral administration of taxoids |
| 02/17/2005 | WO2005013967A1 Medicaments comprising pde iv inhibitors and a novel anticholinergic and their use for treating respiratory disorders |
| 02/17/2005 | WO2005013966A1 Macrophage activation inhibitor |
| 02/17/2005 | WO2005013965A1 Use of cis-99, trans-11 isomer of conjugated linoleic acid (cla) for treating inflammatory diseases |
| 02/17/2005 | WO2005013964A1 Pharmaceutical preparation containing nateglinide |
| 02/17/2005 | WO2005013963A1 Advantageous combinations for inhalation of nacystelyn and bronchodilators |
| 02/17/2005 | WO2005013960A1 Preparing method for controlled released type tablet tamsulosin hcl and the tablet thereof |
| 02/17/2005 | WO2005013959A1 Veterinary aqueous injectable suspensions containing florfenicol |
| 02/17/2005 | WO2005013958A1 Histone deacetylase inhibitors as immunosuppressants |
| 02/17/2005 | WO2005013957A2 Solid dispersible and/or orodispersible non-filmy containing at least one type of active substance pharmaceutical composition and method for the preparation thereof |
| 02/17/2005 | WO2005013955A2 Topical composition comprising terbinafine and hydrocortisone |
| 02/17/2005 | WO2005013954A1 Modified release venlafaxine hydrochloride tablets |
| 02/17/2005 | WO2005013953A1 Extended release venlafaxine besylate tablets |
| 02/17/2005 | WO2005013952A1 Therapeutic use of bicycloheptane derivatives |
| 02/17/2005 | WO2005013951A2 Pharmaceutical compositions for preventing breast and ovarian cancer |
| 02/17/2005 | WO2005013950A2 Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases |
| 02/17/2005 | WO2005013949A2 Method for treating cachexia with retinoid ligands |
| 02/17/2005 | WO2005013948A2 Method of treating acute myocardial infarction |
| 02/17/2005 | WO2005013947A2 Means and methods for treating a disease which is associated with an excess transport of hyaluronan across a lipid bilayer |
| 02/17/2005 | WO2005013946A2 Methods of treatment inflammatory bowel with lxr agonists |
| 02/17/2005 | WO2005013945A2 Medicaments for inhalation comprising steroids and a betamimetic |
| 02/17/2005 | WO2005013942A1 Compositions comprising components coated with a liquid impermeable but gas permeable layer, use thereof for treating cutaneous and other exocrine gland diseases |
| 02/17/2005 | WO2005013940A1 Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin |
| 02/17/2005 | WO2005013937A2 Novel compositions of sildenafil free base |
| 02/17/2005 | WO2005013932A1 Use of spermine and/or spermidine against skin ageting in dietary, pharmaceutical or cosmetic compositions |
| 02/17/2005 | WO2005013930A1 Parasiticidal composition |
| 02/17/2005 | WO2005013928A1 Composition and method for promoting hair growth |
| 02/17/2005 | WO2005013919A2 Treatment using dantrolene |
| 02/17/2005 | WO2005013918A2 Compositions, methods and kits relating to poxvirus subunit vaccines |
| 02/17/2005 | WO2005013914A2 Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| 02/17/2005 | WO2005013911A2 Protective and therapeutic uses for tocotrienols |
| 02/17/2005 | WO2005013910A2 Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors |
| 02/17/2005 | WO2005013909A2 Novel cathepsin k inhibitors |
| 02/17/2005 | WO2005013908A2 Neuroprotection protects against cellular apoptosis, neural stroke damage, alzheimer’s disease and retinal degeneration |
| 02/17/2005 | WO2005013907A2 Pyrrolo[1,2-b]pyridazine derivatives |
| 02/17/2005 | WO2005013905A2 SENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ssRNA VIRAL INFECTION |
| 02/17/2005 | WO2005013903A2 Derivatives of substituted quinone and uses thereof |
| 02/17/2005 | WO2005013902A2 Methods and compositions for inhibiting the proliferation of prostate cancer cells |
| 02/17/2005 | WO2005013900A2 Method and composition for treating peridontal disease |
| 02/17/2005 | WO2005013892A2 Hydrolytically-resistant boron-containing therapeutics and methods of use |
| 02/17/2005 | WO2005013889A2 Truncated fragments of alpha-synuclein in lewy body disease |
| 02/17/2005 | WO2005013888A2 Compounds, compositions and methods |
| 02/17/2005 | WO2005013886A2 Methods for treating and preventing apoptosis-related diseases using rna interfering agents |
| 02/17/2005 | WO2005013884A2 Methods for preventing neurological events |